First evaluation of fibroblast growth factor 21 levels in patients diagnosed with glycogen storage diseases with
Abdullah Bozkurt1,2, Esra Kara3,4, Fatma Derya Bulut3
1Department of Pediatrics, Faculty of Medicine, Çukurova University, Adana, Türkiye.
Objectives:
Glycogen storage diseases (GSDs) are inherited metabolic disorders caused by deficiencies in the enzymes responsible for glycogen synthesis and breakdown. GSD subtypes involving the liver are commonly associated with symptoms such as fasting hypoglycemia and hepatomegaly, and medical nutrition therapy remains the gold standard of treatment. Fibroblast growth factor 21 (FGF21), a hormone primarily secreted by the liver, plays a key role in regulating lipid, glucose, and energy metabolism. This study measured FGF21 levels in patients with hepatic forms of GSD at Çukurova University, evaluating differences among GSD subtypes and their correlations with biochemical parameters.
Methods:
The study included 50 patients with hepatic GSD who were categorized by subtypes: 10 with type Ia, 2 with type Ib, 16 with type III, 3 with type VI, 8 with type IXa, 4 with type IXb, and 7 with type IXc. Serum FGF21 levels were measured, and their associations with biochemical findings, abdominal imaging results, and growth parameters were evaluated.
Results:
Of the 50 patients, 52 % were female and 48 % male. The mean age at admission was 142.26 ± 76.19 months (range: 23-360 months). Common reasons for admission included abdominal distension, hepatomegaly, hypoglycemia, and growth retardation. The average FGF21 level across all patients was 318.3 ± 126.9 pg/mL, with the highest levels observed in patients with GSD type IXc (464.31 ± 112.88 pg/mL), followed by those with type IXa (343.35 ± 137.18 pg/mL) and type III (323.80 ± 116.04 pg/mL). Patients with GSD type IXc had significantly higher FGF21 levels than those with other subtypes (p=0.001).
Conclusions:
This is the first study to evaluate FGF21 levels in patients with GSD. FGF21 levels in this cohort were comparable to those observed in patients with acute fatty liver disease and hepatosteatosis. Although no statistically significant differences were observed across most GSD subtypes, patients with GSD type IXc exhibited notably higher FGF21 levels, indicating that FGF21 may serve as a biomarker for identifying more severe phenotypes of GSD.
